AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11167438
Drug: Droperidol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.5 mg at induction and droperidol 0.05 mg per 1-mg bolus dose of morphine
Trial: 9924238
Drug: itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: itraconazole 200 mg orally, once daily for 4 days
Trial: 7508827
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium chloride (0.3 mEq/kg bolus over 10 minutes followed by 0.08 mEq/kg per hour for 24 hours)
Trial: 7508827
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium chloride
Trial: 2906956
Drug: labetalol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol (1 mg/kg i.v. 15 min)
Trial: 24726210
Drug: losartan 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 150 mg/d
Trial: 24726210
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg/d
Trial: 23275363
Drug: Exenatide once
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide once weekly (EQW) 2 mg
Trial: 23275363
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (once or twice daily, titrated)
Trial: 10974044
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (200 mg of DHA/day)
Trial: 8733069
Drug: Carvedilol 50
RxNorm normalized name: carvedilol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 50 mg bid
Trial: 16598518
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg bid
Trial: 8733069
Drug: Intravenous carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous carvedilol followed by oral carvedilol 50 mg bid for 8 weeks
Trial: 1303781
Drug: Immunologically active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunologically active peat preparation (PTT)
Trial: 26946967
Drug: Probiotic S.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic S. boulardii (50 mg/kg twice daily)
Trial: 19822590
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery treatment
Trial: 19822590
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery treatment after standard medical care
Trial: 19822590
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery treatment effects maintained for 6 months
Trial: 15190043
Drug: High-flavonoid dark
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavonoid dark chocolate (213 mg procyanidins, 46 mg epicatechin)
Trial: 15190043
Drug: Low-flavonoid dark
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavonoid dark chocolate (46 g, 1.6 oz)
Trial: 11735841
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus a 15-session group cognitive therapy prevention program
Trial: 8192116
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of ondansetron (0.15 mg/kg) with dexamethasone (20 mg)
Trial: 8192116
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of ondansetron (0.15 mg/kg) with dexamethasone (20 mg)
Trial: 25231632
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (COC) users
Trial: 31983034
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose COCs (20 mcg EE)
Trial: 27926561
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate ointment (twice daily for 8 weeks)
Trial: 23525894
Drug: MK-7 (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7 (180 μg MK-7/day)
Trial: 19682342
Drug: IV ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ferric carboxymaltose (≤1000 mg over 15 min, repeated weekly)
Trial: 18928998
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (325 mg orally thrice daily for 6 weeks)
Trial: 16769917
Drug: Life-prolonging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life-prolonging therapy from the ICD
Trial: 12572702
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy following surgery
Trial: 11795434
Drug: Finasteride (5-alpha-reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5-alpha-reductase inhibitor)
Trial: 9397979
Drug: Lactulose (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (45 mL/d) for 8 weeks
Trial: 31268011
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy
Trial: 27058907
Drug: Medication Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Therapy Management review and CVD risk assessment and education
Trial: 25504176
Drug: Dyadic music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dyadic music therapy intervention (10 weekly sessions)
Trial: 22824755
Drug: Fermented papaya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented papaya preparation (FPP) 9g/day (4.5g twice a day sublingually) for 6 weeks
Trial: 28810801
Drug: Fermented papaya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented papaya preparation (FPP)
Trial: 20846428
Drug: Weekly CCQ
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly CCQ assessment
Trial: 15956086
Drug: naloxone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone (8 mg) preceding beta-endorphin infusion
Trial: 2692962
Drug: HRP112 (depot‐medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRP112 (depot‐medroxyprogesterone acetate, 25 mg and estradiol cypionate, 5 mg)
Trial: 48894
Drug: Procainamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (500 mg, 4-hourly)
Trial: 48894
Drug: Mexiletine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (250 mg, 8-hourly)
Trial: 29148088
Drug: Intensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intervention (four weekly group sessions and two motivational follow-up calls)
Trial: 22856637
Drug: 0.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/day of jet‐nebulized budesonide inhalation suspension (BIS)
Trial: 22856637
Drug: 40-60 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-60 mg/day of cromolyn sodium inhalation suspension (CIS)
Trial: 15934131
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy and telephone contact
Trial: 9183510
Drug: Group-based relapse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based relapse prevention (G-RP)
Trial: 9183510
Drug: Relapse prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse prevention treatment (both formats)
Trial: 29405780
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (HP: 2.5 g·kg‐1·day‐1; n=8)
Trial: 29405780
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (LP: 0.9 g·kg‐1·day‐1; n=9)
Trial: 24112515
Drug: Nevirapine XR
RxNorm normalized name: nevirapine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine XR formulation
Trial: 20467878
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine with 4 mg dexamethasone (group BD)
Trial: 9646062
Drug: Amorphous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amorphous erythromycin ethylsuccinate (500 mg)
Trial: 9646062
Drug: Crystalline erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crystalline erythromycin ethylsuccinate (1000 mg)
Trial: 7884020
Drug: Cocaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (20 mg and 40 mg)
Trial: 7884020
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and cocaine
Trial: 3220956
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg meclizine
Trial: 73796
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of 16 g guar and 10 g pectin to the control meal
Trial: 73796
Drug: Control meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meal containing 106 g carbohydrate
Trial: 19627897
Drug: Concurrent use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent use of ankle support with wedged insole
Trial: 17119140
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment individualized to the patient
Trial: 17119140
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (surgery and nonoperative)
Trial: 15149345
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline albuminuria (> or =3.0 g/g creatinine)
Trial: 16412866
Drug: Aspirin 30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 30, 100, or 325 mg/day
Trial: 11484571
Drug: Aluminous oxide
RxNorm normalized name: aluminium oxide
DrugBank: Aluminum oxide (DB11342)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminous oxide pink stone surface treatment
Trial: 11484571
Drug: 50‐micron aluminum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50‐micron aluminum oxide sandblasting surface treatment
Trial: 11484571
Drug: Brown rubber
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brown rubber point surface treatment
Trial: 11484571
Drug: Gray silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gray silicone wheel followed by pink silicone wheel surface treatment
Trial: 2849376
Drug: Intranasally administered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally administered rhinovirus receptor murine monoclonal antibody (RRMA) 135 micrograms/subject in 9 applications, -17 to +48 h
Trial: 2849376
Drug: Intranasally administered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally administered rhinovirus receptor murine monoclonal antibody (RRMA) 1 mg/subject in 10 applications, -3 to +36 h
Trial: 15004731
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg b.i.d. for 6 days
Trial: 15004731
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg b.i.d. for 6 days
Trial: 1546725
Drug: Mealtime antacids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mealtime antacids (80 mmol/day)
Trial: 1546725
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g twice a day
Trial: 1546725
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg, antacids, ranitidine 150 mg, and sucralfate
Trial: 9691103
Drug: Mesalamine 2
RxNorm normalized name: mesalamine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 2 g twice daily
Trial: 24929350
Drug: Pegnivacogin 1
RxNorm normalized name: Pegnivacogin
DrugBank: Pegnivacogin (DB06293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegnivacogin 1 mg/kg with 25% anivamersen reversal
Trial: 24929350
Drug: Pegnivacogin 1
RxNorm normalized name: Pegnivacogin
DrugBank: Pegnivacogin (DB06293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegnivacogin 1 mg/kg with 50% anivamersen reversal
Trial: 24929350
Drug: Pegnivacogin 1
RxNorm normalized name: Pegnivacogin
DrugBank: Pegnivacogin (DB06293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegnivacogin 1 mg/kg with 75% anivamersen reversal
Trial: 24929350
Drug: Pegnivacogin 1
RxNorm normalized name: Pegnivacogin
DrugBank: Pegnivacogin (DB06293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegnivacogin 1 mg/kg with 100% anivamersen reversal
Trial: 20559104
Drug: Tiopronin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiopronin (3 g/d)
Trial: 20559104
Drug: Tiopronin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiopronin (1 g/d to 3 g/d)
Trial: 15673873
Drug: Stimulation patterns
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation patterns (300‐500 V; 100‐1000 Hz; 1‐5 stimuli) at different propofol target plasma concentrations (PTPCs) (2, 4, and 6 microg/mL)
Trial: 15673873
Drug: Propofol target
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target plasma concentrations (PTPCs) (2, 4, and 6 microg/mL)
Trial: 2268862
Drug: Ketoprofen 75
RxNorm normalized name: ketoprofen 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 75 mg
Trial: 30961672
Drug: 4 active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 active ABCR sessions twice a week
Trial: 30961672
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group sessions twice a week
Trial: 25694300
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro protamine
Trial: 23404154
Drug: Left capnothorax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left capnothorax first (Group L)
Trial: 18847131
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment with antidepressants (specifics not provided)
Trial: 12929879
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake in children with rickets (285 +/- 113 mg/day)
Trial: 12929879
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake in adolescents with rickets (305 +/- 196 mg/day)
Trial: 12929879
Drug: 25 hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 hydroxyvitamin D in children with rickets (49 +/- 38 nmol/l)
Trial: 12929879
Drug: Serum 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25 hydroxyvitamin D in adolescents with rickets (12.6 +/- 7.1 nmol/l)
Trial: 12929879
Drug: Odds ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odds ratio for developing rickets with daily calcium intake below 300 mg
Trial: 12929879
Drug: Calcium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium treatment (1 g daily) in children
Trial: 12929879
Drug: Calcium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium treatment (1 g daily) in adolescents
Trial: 1357124
Drug: sCD4 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCD4 plus dideoxyinosine (90 mg/m2 every 8 hours)
Trial: 1357124
Drug: sCD4 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCD4 plus dideoxyinosine combination therapy
Trial: 2409543
Drug: Flecainide acetate
RxNorm normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide acetate (200 mg twice daily)
Trial: 27852545
Drug: Synbiotic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic preparation containing Lactobacillus casei, L. plantarum, L. rhamnosus, Bifidobacterium lactis and prebiotics
Trial: 27852545
Drug: Zinc suspension
RxNorm normalized name: Human insulin zinc suspension crystalline
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc suspension (15 mg/day for 5 days)
Trial: 27852545
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ORS and/or intravenous therapy)
Trial: 23242727
Drug: Hydrocortisone +
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone + mupirocin ointment
Trial: 23242727
Drug: Emollient ointment
RxNorm normalized name: diflorasone
DrugBank: Diflorasone (DB00223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient ointment
Trial: 18798830
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) intravenous (i.v.)
Trial: 18798830
Drug: Phenytoin (PHT)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin (PHT) intravenous (i.v.)
Trial: 15849424
Drug: Apple polyphenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple polyphenol (Ap) 500 mg once daily for 12 weeks
Trial: 7745785
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia plus epidural anesthesia (bupivacaine 0.25% with 200,000 epinephrine, 0.75 ml.kg‐1)
Trial: 7010929
Drug: Gemfibrozil (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (1200 mg daily for 3 months)
Trial: 31479722
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg subcutaneously, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg.
Trial: 31479722
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg.
Trial: 15073451
Drug: Rosuvastatin (Crestor)
RxNorm normalized name: rosuvastatin Oral Tablet [Crestor]
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (Crestor) 5-40 mg
Trial: 11284474
Drug: Current protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current protocol (gastric residual volume threshold, 150 mL, optional prokinetic)
Trial: 11284474
Drug: Proposed feeding
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed feeding protocol (gastric residual volume threshold 250 mL, mandatory prokinetic)
Trial: 3548735
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement (MaxEPA)
Trial: 12712108
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg (twice daily)
Trial: 12712108
Drug: Sulindac 200
RxNorm normalized name: sulindac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 200 mg (twice daily)
Trial: 12712108
Drug: Nimesulide 200
RxNorm normalized name: nimesulide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 200 mg (twice daily)
Trial: 8160602
Drug: Mexiletine (720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (720 mg/day)
Trial: 27670863
Drug: Therapeutic aerobic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic aerobic exercise with music therapy (G1)
Trial: 25447467
Drug: Tobacco Tactics
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco Tactics website with nurse counseling by phone and access to nicotine replacement therapy (NRT)
Trial: 20668455
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day; n=15)
Trial: 17436360
Drug: Xiong‐gui‐tiao‐xue‐yin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiong‐gui‐tiao‐xue‐yin at a dose of 6.0 g/day (Group X)
Trial: 15464183
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further chemotherapy (n=200)
Trial: 15464183
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (n=210)